Axsome Therapeutics vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?

Choosing between a commercial-stage drugmaker and a clinical biotech requires balancing current sales against potential. For investors, Axsome Therapeutics (NASDAQ:AXSM) and Revolution Medicines (NASDAQ:RVMD) offer two distinct paths toward growth.

Axsome focuses on central nervous system disorders with several products already on the market generating meaningful cash. Revolution Medicines is a clinical-stage oncology firm targeting difficult-to-treat cancers through its proprietary platform. While both operate in a high-stakes industry, their financial profiles and overall maturity levels differ significantly.

The case for Axsome Therapeutics

Axsome develops therapies for central nervous system conditions like depression and migraine. It currently commercializes three products in the United States, including Auvelity and Sunosi. This dual approach of internal development and licensing allows it to scale quickly among biotech stocks.

In FY 2025, revenue reached nearly $638.5 million, representing a 65.5% increase compared to the prior year. Despite this rapid top-line growth, the company reported a net loss of approximately $183.2 million. This resulted in a negative net margin of roughly 28.7%, which measures how much revenue remains after all expenses are paid.

As of its December 2025 balance sheet, the debt-to-equity ratio is close to 2.7x. This metric compares total debt to shareholder equity, and a value over 1.0 indicates the company uses more debt than equity to fund its assets. The current ratio, which measures the ability to cover short-term obligations, is about 1.6x, and free cash flow was negative $93.9 million.

The case for Revolution Medicines

Revolution Medicines is an oncology-focused company building a pipeline of oral inhibitors to treat RAS-addicted cancers. Unlike its peer, it currently has no products approved for commercial sale and has generated no revenue from drug sales. The company relies on third-party manufacturers for clinical supplies while its 883 employees focus heavily on research and development.

In FY 2025, revenue reached $0.0 as the company remained in the clinical stage without commercial products. Consequently, it reported a net loss of nearly $1.1 billion for the year. This net loss widened from approximately $600.1 million in fiscal 2024 as the company ramped up spending on its late-stage clinical programs for pancreatic and lung cancer.

As of its December 2025 balance sheet, the company maintains a low debt-to-equity ratio of roughly 0.1x. This ratio compares total debt to shareholder equity, indicating a very low reliance on borrowed funds. Its current ratio is a robust 7.1x, and free cash flow was negative $913.7 million in FY 2025 as the company invested in its pipeline.

Risk profile comparison

Axsome faces risks related to its history of net losses and its limited history of commercializing drugs independently. Regulatory hurdles also persist, as seen with previous challenges regarding its fibromyalgia candidate. Furthermore, the company faces intense competition in the central nervous system market from established players like AbbVie (NYSE:ABBV), Biogen (NASDAQ:BIIB), Eli Lilly, and Jazz Pharmaceuticals.

Revolution Medicines carries the high risk typical of clinical-stage biotechs, including the potential for trial failures or the emergence of drug resistance. Without any current product revenue, it is entirely dependent on its ability to raise additional capital. It also competes with large pharmaceutical firms like Amgen (NASDAQ:AMGN) and faces manufacturing risks related to regulatory changes like the BIOSECURE Act.

Valuation comparison

Axsome Therapeutics commands a premium valuation relative to its current sales. Revolution Medicines is an early stage business that is not yet generating the forecasted earnings or revenue needed to calculate these metrics.

Valuation metrics sourced from Financial Modeling Prep (FMP) and may differ from other data providers.

Which stock would I buy in 2026?

I'd go with Revolution Medicines. In 2026, it achieved something that had eluded oncologists for decades: FDA approval for daraxonrasib, the first-ever targeted therapy for metastatic pancreatic cancer. A breakthrough like that defines a company's trajectory for years.

Revenue is still modest, but the addressable patient population is expanding. A Royalty Pharma partnership provides funding without further diluting shareholders, and the pipeline extends into lung cancer and other RAS-driven tumors that could add multiple new growth engines over time.

Axsome has made genuine strides since launching its first commercial drugs. A new FDA approval for Alzheimer's agitation adds a promising indication, and revenue is growing at a healthy clip. That said, the most recent quarter saw results come in below analyst expectations, losses widened as selling costs surged, and the path to profitability still requires everything to keep clicking commercially.

Both companies are asking investors to be patient. The difference is that Revolution Medicines is being patient around a drug that just changed the standard of care for a devastating disease. Investors with a long time horizon will find that a more compelling foundation to build on.

Sara Appino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AbbVie, Amgen, Axsome Therapeutics, and Eli Lilly. The Motley Fool recommends Biogen. The Motley Fool has a disclosure policy.